Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Abstract Introduction Pirfenidone is an oral antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). Real-world data on adverse event (AE) management for pirfenidone are limited. Strategies for managing potential antifibrotic therapy AEs were examined in a sample of US pulmonologists. M...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2018-06-01
|
Series: | Pulmonary Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s41030-018-0056-8 |